Researchers at the University of Birmingham have shown that it’s possible to produce a compound with anti-cancer properties directly from feverfew – a common flowering garden plant.
The team was able to extract the compound from the flowers and modify it so it could be used to kill chronic lymphocytic leukaemia (CLL) cells in the laboratory.
Feverfew is grown in many UK gardens, and also commonly sold in health food shops as a remedy for migraine and other aches and pains.
The compound the Birmingham team were investigating is called parthenolide and was identified by scientists as having anti-cancer properties several years ago. Although available commercially, it is extremely expensive with poor “drug-like” properties and has not progressed beyond basic research.
The Birmingham team were able to show a method not only for producing the parthenolide directly from plants, but a way of modifying it to produce a number of compounds that killed cancer cells in in vitro experiments. The particular properties of these compounds make them much more promising as drugs that could be used in the clinic.
The parthenolide compound appears to work by increasing the levels of reactive oxygen species (ROS) in cells. Cancer cells already have higher levels of these unstable molecules and so the effect of the parthenolide is to increase levels of these to a critical point, causing the cell to die.
The study, published in MedChemCom, was a multidisciplinary programme, drawing together researchers from the University’s Institute of Cancer and Genomic Studies and the School of Chemistry. The University of Birmingham’s Winterbourne Botanic Garden oversaw the cultivation of the plants in sufficient volume for the drug screen to take place.
It was initiated by Angelo Agathanggelou, of the Institute of Cancer and Genomic Studies, who is investigating new ways to treat chronic lymphocytic leukaemia (CLL), a type of cancer which typically affects older people and which becomes resistant to treatment over time.
“We were interested in finding out more about the potential of parthenolide,” says Agathanggelou. “With expertise from colleagues in the School of Chemistry we’ve been able to demonstrate that this compound shows real promise and could provide alternative treatment options for CLL patients.”